MX2019009717A - Composicion farmaceutica. - Google Patents
Composicion farmaceutica.Info
- Publication number
- MX2019009717A MX2019009717A MX2019009717A MX2019009717A MX2019009717A MX 2019009717 A MX2019009717 A MX 2019009717A MX 2019009717 A MX2019009717 A MX 2019009717A MX 2019009717 A MX2019009717 A MX 2019009717A MX 2019009717 A MX2019009717 A MX 2019009717A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- methylquinoline
- phenylacetyl
- carboxamide
- phenoxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención resuelve el problema de proporcionar una composición farmacéutica que tenga una excelente estabilidad, propiedades desintegrantes y capacidad de absorción, que se pueda preparar fácilmente y que contenga la 4-(2-fluoro-4-(3-(2-fenilace til)tioureido)fenoxi)-7-metoxi-N-metilquinolina-6-carboxamida o una de sus sales farmacéuticamente aceptables y un derivado de ciclodextrina. La presente invención se refiere a una composición farmacéutica que contiene la 4-(2-fluoro-4-(3-(2-fenilacetil)tiour eido) fenoxi)-7-metoxi-N-metilquinolina-6-carboxamida o una de sus sales farmacéuticamente aceptables e hidroxipropil-ß-ciclodext rina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017026203 | 2017-02-15 | ||
| PCT/JP2018/005140 WO2018151177A1 (ja) | 2017-02-15 | 2018-02-14 | 医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019009717A true MX2019009717A (es) | 2019-10-02 |
| MX383728B MX383728B (es) | 2025-03-14 |
Family
ID=63169269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007061A MX2021007061A (es) | 2017-02-15 | 2018-02-14 | Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina. |
| MX2019009717A MX383728B (es) | 2017-02-15 | 2018-02-14 | Composicion farmaceutica. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007061A MX2021007061A (es) | 2017-02-15 | 2018-02-14 | Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11110062B2 (es) |
| EP (1) | EP3583943B1 (es) |
| JP (1) | JP6771594B2 (es) |
| KR (2) | KR102323255B1 (es) |
| CN (2) | CN110312511B (es) |
| AU (1) | AU2018222163C1 (es) |
| CA (1) | CA3053739C (es) |
| DK (1) | DK3583943T3 (es) |
| ES (1) | ES2991062T3 (es) |
| FI (1) | FI3583943T3 (es) |
| HU (1) | HUE068810T2 (es) |
| MA (1) | MA47516A (es) |
| MX (2) | MX2021007061A (es) |
| MY (1) | MY194278A (es) |
| PH (1) | PH12019501873A1 (es) |
| PL (1) | PL3583943T3 (es) |
| PT (1) | PT3583943T (es) |
| SG (1) | SG11201907433TA (es) |
| TW (1) | TWI702951B (es) |
| WO (1) | WO2018151177A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3053739C (en) | 2017-02-15 | 2023-02-14 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| JP7074760B2 (ja) | 2017-09-08 | 2022-05-24 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| MA53667A (fr) | 2018-09-18 | 2021-07-28 | Taiho Pharmaceutical Co Ltd | Polythérapie associant un composé d'acylthiourée et de l'abiratérone |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| US20230307804A1 (en) | 2021-03-12 | 2023-09-28 | Lg Energy Solution, Ltd. | Bus bar assembly, battery pack comprising bus bar assembly, and vehicle comprising battery pack |
| US20230114887A1 (en) | 2021-10-12 | 2023-04-13 | Lg Energy Solution, Ltd. | Battery pack and vehicle including the same |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254541A (en) | 1991-11-15 | 1993-10-19 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indole/cyclodextrin complex |
| CN1154070A (zh) * | 1994-05-27 | 1997-07-09 | 荷兰发马克有限公司 | 药物组合物 |
| WO2001047890A1 (en) | 1999-12-24 | 2001-07-05 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| CA2454538A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| SE520606C2 (sv) | 2001-06-26 | 2003-07-29 | Flir Systems Ab | Förfarande för att åstadkomma en spegelyta, samt spegel med sådan spegelyta |
| JP2003238592A (ja) | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| CN1448053A (zh) | 2003-04-22 | 2003-10-15 | 西安敬业生物药物科技有限公司 | 甲基托布津包络物农药制剂 |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| CN1906166A (zh) | 2004-02-27 | 2007-01-31 | 卫材株式会社 | 新型吡啶衍生物及嘧啶衍生物(1) |
| WO2005105044A1 (en) * | 2004-04-30 | 2005-11-10 | Ranbaxy Laboratories Limited | Process for making inclusion complex of sulfonylureas having improved aqueous solubility |
| WO2005121125A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN100448053C (zh) * | 2004-08-31 | 2008-12-31 | 清华大学 | 含有屏蔽掩膜支撑体的有机电致发光器件及其制备方法 |
| AU2006229343A1 (en) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| WO2009053737A2 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| CN101491240A (zh) * | 2008-01-25 | 2009-07-29 | 国家农产品保鲜工程技术研究中心（天津） | 提高纳他霉素作用效率的方法 |
| MX2010008187A (es) | 2008-01-29 | 2010-08-10 | Eisai R&D Man Co Ltd | Uso combinado de inhibidor de angiogenesis y taxano. |
| MX2010009669A (es) | 2008-03-06 | 2010-09-22 | Genentech Inc | Terapia de combinacion con antagonistas de c-met y egfr. |
| DK2287155T3 (da) | 2008-04-10 | 2013-07-29 | Taiho Pharmaceutical Co Ltd | Acylthiourea-forbindelse eller salt deraf samt anvendelse deraf |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| EP2288383A1 (en) | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| WO2010056872A2 (en) * | 2008-11-15 | 2010-05-20 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compositions |
| CN102481299B (zh) | 2009-02-12 | 2015-02-25 | 艾科尔公司 | 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物 |
| CN101926808A (zh) | 2009-06-25 | 2010-12-29 | 积华药业有限公司 | 氨基葡萄糖制剂 |
| ES2608329T3 (es) | 2010-02-03 | 2017-04-07 | Incyte Holdings Corporation | Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met |
| NZ604306A (en) | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| CN102274189A (zh) * | 2011-07-21 | 2011-12-14 | 瑞普（天津）生物药业有限公司 | 一种含有癸氧喹酯的干混悬剂组方及其制备方法 |
| WO2013058303A1 (ja) | 2011-10-18 | 2013-04-25 | ラクオリア創薬株式会社 | 医薬組成物 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| CA2915445C (en) | 2013-07-19 | 2024-04-23 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| CN106255510A (zh) | 2014-03-05 | 2016-12-21 | 百时美施贵宝公司 | 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌 |
| EP3226869A4 (en) | 2014-12-03 | 2018-07-18 | Auckland UniServices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| JP2016196411A (ja) | 2015-03-04 | 2016-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| DK3290405T3 (da) * | 2015-04-30 | 2021-03-22 | Taiho Pharmaceutical Co Ltd | Mesylsyresalt af acylthioureaforbindelse, krystal deraf og fremgangsmåder til fremstilling deraf |
| WO2016208744A1 (ja) | 2015-06-25 | 2016-12-29 | 大鵬薬品工業株式会社 | 線維症治療剤 |
| JP6804832B2 (ja) | 2015-07-21 | 2020-12-23 | 東芝ライフスタイル株式会社 | 冷蔵庫 |
| CN106551911A (zh) | 2015-09-21 | 2017-04-05 | 天津市汉康医药生物技术有限公司 | 一种稳定的乐伐替尼药物组合物及其制备方法 |
| CA3053739C (en) | 2017-02-15 | 2023-02-14 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
-
2018
- 2018-02-14 CA CA3053739A patent/CA3053739C/en active Active
- 2018-02-14 MA MA047516A patent/MA47516A/fr unknown
- 2018-02-14 MX MX2021007061A patent/MX2021007061A/es unknown
- 2018-02-14 PL PL18755023.1T patent/PL3583943T3/pl unknown
- 2018-02-14 AU AU2018222163A patent/AU2018222163C1/en active Active
- 2018-02-14 JP JP2018568583A patent/JP6771594B2/ja active Active
- 2018-02-14 SG SG11201907433TA patent/SG11201907433TA/en unknown
- 2018-02-14 WO PCT/JP2018/005140 patent/WO2018151177A1/ja not_active Ceased
- 2018-02-14 MX MX2019009717A patent/MX383728B/es unknown
- 2018-02-14 DK DK18755023.1T patent/DK3583943T3/da active
- 2018-02-14 KR KR1020197023592A patent/KR102323255B1/ko active Active
- 2018-02-14 FI FIEP18755023.1T patent/FI3583943T3/fi active
- 2018-02-14 CN CN201880012000.XA patent/CN110312511B/zh active Active
- 2018-02-14 PT PT187550231T patent/PT3583943T/pt unknown
- 2018-02-14 HU HUE18755023A patent/HUE068810T2/hu unknown
- 2018-02-14 MY MYPI2019004652A patent/MY194278A/en unknown
- 2018-02-14 CN CN202311298292.7A patent/CN117137915A/zh active Pending
- 2018-02-14 KR KR1020217035697A patent/KR20210135354A/ko not_active Ceased
- 2018-02-14 ES ES18755023T patent/ES2991062T3/es active Active
- 2018-02-14 TW TW107105612A patent/TWI702951B/zh active
- 2018-02-14 EP EP18755023.1A patent/EP3583943B1/en active Active
- 2018-02-14 US US16/485,971 patent/US11110062B2/en active Active
-
2019
- 2019-08-13 PH PH12019501873A patent/PH12019501873A1/en unknown
-
2021
- 2021-06-15 US US17/347,989 patent/US12144892B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009717A (es) | Composicion farmaceutica. | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| MX2018000412A (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| DK3513809T3 (da) | Medicinsk sammensætning, som omfatter tivozanib | |
| BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| BR112018005742A2 (pt) | composição tópica, método para desinfecção de uma superfície, utilização da composição e utilizações de uma composição | |
| MX392182B (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| BR112017016084A2 (pt) | composição e método para o tratamento da doença veno-oclusiva hepática | |
| EA201890186A1 (ru) | Применение штаммов микробактерий для получения антибактериальных агентов | |
| MX2019001781A (es) | Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. | |
| MX2017007420A (es) | Composiciones para el cuidado bucal con alto contenido de agua y micro resistencia. | |
| MX388559B (es) | Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular. | |
| CL2016003023A1 (es) | “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct | |
| CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| MX2018000212A (es) | Metodos para el control de la sarna del manzano. | |
| CL2020000586A1 (es) | Moduladores de la expresión de enac. | |
| BR112016015578A2 (pt) | Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2 | |
| CL2019001859A1 (es) | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta. | |
| UA130333C2 (uk) | Композиції, які містять кромогліцієву кислоту, для лікування дерматиту | |
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза |